About Anavex
Anavex is a publicly listed company based in New York (United States) founded in 2004. Therapeutics for neurodegenerative diseases are developed using sigma receptor targeting. The company has 42 employees. Its website anavex.com draws about 23 thousand monthly visits. Anavex offers products and services including Blarcamesine and SIGMACEPTOR Platform. Its focus areas include Life Sciences, Neurology, Drugs and Neurodegenerative. Its legal entity is Anavex Life Sciences Corp.
Company details
Anavex was founded in 2004 and is headquartered in New York, United States. Operations focus on the biotechnology sector, where therapeutics for neurodegenerative diseases are developed through the proprietary SIGMACEPTOR discovery platform. This platform facilitates the identification of novel chemical entities that target sigma receptors. The lead candidate, ANAVEX, is advanced for treating Alzheimers disease and related dementia conditions.
- Headquarters New York, United States
- Employees 42
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website anavex.com
- Social LinkedIn X Facebook Instagram
- Legal Name Anavex Life Sciences Corp.
- Net Profit-$46.38 M (USD)-7.85as on Sep 30, 2025
- EBITDA-$51.41 M (USD)2.78as on Sep 30, 2025
- Latest Funding Round$995.86K (USD), Grant
Jan 2021
- Investors
- Employee Count42
Products & Services of Anavex
Anavex offers a comprehensive portfolio of products and services, including Blarcamesine and SIGMACEPTOR Platform.
Activates Sigma-1 receptor to improve autophagy in CNS diseases.
Develops compounds for modulating SIGMAR1 in neurodegenerative conditions.
Funding Insights of Anavex
- Total Rounds 7
- Last Round Grant — $995,862
- First Round $500,000
(Jul 2010)
- Investors Count 1
All 7 funding rounds of Anavex with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2021 | $995,862 | Grant | – | – | |
| Aug 2020 | Post-IPO | – | – | – | |
| Apr 2014 | $10M | Post-IPO | – | – | – |
| Jul 2013 | $2.6M | Post-IPO | – | – | – |
| Feb 2012 | Post-IPO | – | – | – | |
| Nov 2010 | $49,500 | Post-IPO | – | – | – |
| Jul 2010 | $500,000 | Post-IPO | – | – | – |
1 investors in total: 1 institutional.
Investors in Anavex
Anavex has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include The Michael J. Fox Foundation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Research for Parkinson's disease is funded by the foundation. | 2000 | michaeljfox.org | New York, United States |
Investor details for Anavex
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Anavex
39 people are tracked at Anavex (20 in leadership, 16 in board & advisors, 3 in team); the tracked headcount is 42.
| Name | Role | Group |
|---|---|---|
Kun Jin | Vice President and Head of Biostatistics | Leadership |
Walter E Kaufmann | Chief Medical Officer | Leadership |
Christopher Missling | President & CEO | Leadership |
Emmanuel O Fadiran | Senior Vice President of Regulatory Affairs | Leadership |
Terrie Burrell Kellmeyer | Senior Vice President Clinical Development And Regulatory Affairs | Leadership |
Ashley Seragusa | Associate Director, Clinical Data Management | Leadership |
Jeffrey Edwards | Vice President Of Clinical Pharmacology And Science | Leadership |
Stephan Toutain | Senior Vice President of Operations | Leadership |
Daniel Klamer | Vice President of Business Development and Scientific Strategy | Leadership |
Steven P. Neilson | Vice President Clinical Operations | Leadership |
Alani Selvey | Senior Vice President, CMC | Leadership |
Edison Guamba | Associate Director of Clinical Operations | Leadership |
Tapas Saha, PhD | Senior Director, Clinical Development & Medical Communications | Leadership |
Clint Tomlinson | Vice President Operations | Leadership |
Edward Hammond MD, PHD, MPH | Chief Medical Officer | Leadership |
Daniel Klamer, PhD, MBA | vice President, Business Development & Scientific Strategy | Leadership |
Mireilly Figueroa | Executive Director, Clinical Data Management | Leadership |
Shruti B. | Senior Director Clinical Operations | Leadership |
James T. | Associate Director Of Clinical Research | Leadership |
David Jerchower | Vice President Of Clinical Supply | Leadership |
19 more people are available in the full profile.
Complete people profiles for Anavex
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Anavex
Anavex is a publicly listed company on the NASDAQ with ticker symbol AVXL in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date14 Aug 2006
- Listed onNASDAQ: AVXL
- Listed entityAnavex Life Sciences Corp.
- Exchange sectorHealth technology
- ISINUS0327973006
- Share price$1.48 (-1.99% on the day) · 2026-10-13
- Market capitalisation$137.2M
- EPS (diluted, trailing year)$-0.15
- Volume (last session)1,194,823
Financials of Anavex
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -$46.4M | -$51.4M | |
| 2024 | -$43.0M | -$52.9M | |
| 2023 | -$47.5M | -$55.8M | |
| 2022 | -$48.0M | -$51.0M | |
| 2021 | -$37.9M | -$42.0M |
Detailed financial statements for Anavex
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Anavex
4 dated milestones of Anavex across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Anavex is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $500K.
- Funding Latest funding round, Grant, of $996K.
Web traffic of Anavex
The website of Anavex (anavex.com) receives about 23.1K visits a month and ranks #1,188,295 among all websites worldwide, #1,489 in Biotechnology and Pharmaceuticals.
- Monthly visits23.1K
▲ 7% vs previous month
- Unique visitors9.3K
per month
- Global rank#1,188,295
among all websites
- Category rank#1,489
Health · Biotechnology and Pharmaceuticals
- Bounce rate39%
- Pages per visit2.2
- Average visit39 sec
- DevicesDesktop 32% · Mobile 68%
Websites whose visitors overlap most with Anavex. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
phacilitate.co.uk | phacilitate.co.uk | 100% | – | ||
entremed.com | entremed.com | 98% | – | ||
| clinicaltrialsarena.com | 96% | #257,942 | View details | ||
| neurenpharma.com | 96% | 9.6K | #2,553,786 | View details | |
| biotech-careers.org | 96% | #758,383 | View details | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 10 similar websites and full traffic analytics for Anavex
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 10 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Neurology
3 companies that operate in the same segment as Anavex (Neurology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Anavex
Complete news archive for Anavex
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Anavex
Anavex was founded in 2004 and raised its 1st funding round 6 years after it was founded.
Anavex is headquartered in New York, United States. It is registered at New York, New York, United States.
Anavex has 42 employees.
Anavex was founded in 2004 and is headquartered in New York, United States. Operations focus on the biotechnology sector, where therapeutics for neurodegenerative diseases are developed through the proprietary SIGMACEPTOR discovery platform. This platform facilitates the identification of novel chemical entities that target sigma receptors. The lead candidate, ANAVEX, is advanced for treating Alzheimers disease and related dementia conditions.
Anavex offers Blarcamesine and SIGMACEPTOR Platform.
Yes, Anavex is publicly traded on NASDAQ under the ticker symbol AVXL.
Anavex has 1 investor. Key investors include The Michael J. Fox Foundation.
Anavex operates through Anavex Life Sciences Corp.